Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
- Sponsor
- University of Erlangen-Nürnberg Medical School
- Study ID
- NCT06560801
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Chronic Kidney Diseases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10mg Tab — DRUGRandomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
Study Details
The aim of this study is to observe the mechanisms of dapagliflozin on the renal interstitial tissue and renal perfusion. For this purpose, renal transplanted patients as an excellent model of CKD and high cardiovascular risk (similar to patients in DAPA-CKD study) are included in this study. The objectives of the study are to analyze the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal function one year after kidney transplantation. This is a randomized (1:1), single centre clinical study. Each patient will be randomly assigned in an unblinded fashion to 10 mg Dapagliflozin or not 9 months after transplantation. At least 48 patients will be randomized and included. The routine renal biopsy taken one year after kidney transplantation will allow us to determine the morphological integrity of peritubular fibroblasts, interstitial inflammatory cell density and investigate markers of inflammation, oxidative stress and nitic oxide synthase expression (iNOS).
Key Dates
- Start date
- Jul 28, 2023
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: DapagliflozinDapagliflozin + standard of care
- No Intervention: Standard of carestandard of care only
Primary Outcome Measure
renal morphology - fibroblasts [ Time Frame: 3 months after randomization ]
Related Studies
- BLOOM: Biological Legacy of Origin in Mother-Infant DyadsRecruiting · University of Miami · Miami, Florida
- MRI Technical Development and Applications in Kidney DiseaseNot Yet Recruiting · University of Minnesota · Minneapolis, Minnesota
- Partners Calciphylaxis BiobankRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Pioglitazone to Reduce Sympathetic Overactivity in CKD PatientsPHASE4 · Recruiting · The University of Texas at Arlington · Arlington, Texas